Cytokinetics Announces Five Presentations Related to Aficamten at the European Society of Cardiology Congress 2025
Cytokinetics (NASDAQ:CYTK) announced five presentations related to aficamten at the European Society of Cardiology Congress 2025 in Madrid, Spain. The key highlight includes a Hot Line presentation of MAPLE-HCM study results, comparing aficamten versus metoprolol in obstructive HCM patients.
The presentations will feature data from multiple clinical trials including REDWOOD-HCM, SEQUOIA-HCM, and FOREST-HCM, focusing on aficamten's efficacy, safety, and its impact on atrial fibrillation in obstructive hypertrophic cardiomyopathy. The company will host an investor webcast on September 2, 2025 to discuss the MAPLE-HCM results and other presented data.
Cytokinetics (NASDAQ:CYTK) ha annunciato cinque presentazioni sull’aficamten al Congress of the European Society of Cardiology 2025 a Madrid, in Spagna. Tra i momenti salienti figura una presentazione Hot Line dei risultati dello studio MAPLE-HCM, che confronta aficamten e metoprololo in pazienti con CMH ostruttiva.
Le comunicazioni includeranno dati provenienti da diversi trial clinici, tra cui REDWOOD-HCM, SEQUOIA-HCM e FOREST-HCM, con focus sull’efficacia e la sicurezza di aficamten e sul suo effetto sulla fibrillazione atriale nella cardiomiopatia ipertrofica ostruttiva. L’azienda terrà inoltre un webcast per gli investitori il 2 settembre 2025 per discutere i risultati di MAPLE-HCM e gli altri dati presentati.
Cytokinetics (NASDAQ:CYTK) anunció cinco presentaciones sobre aficamten en el Congreso de la Sociedad Europea de Cardiología 2025 en Madrid, España. Uno de los puntos destacados es una presentación Hot Line de los resultados del estudio MAPLE-HCM, que compara aficamten frente a metoprolol en pacientes con CMH obstructiva.
Las presentaciones incluirán datos de varios ensayos clínicos, entre ellos REDWOOD-HCM, SEQUOIA-HCM y FOREST-HCM, centrándose en la eficacia y seguridad de aficamten y su impacto en la fibrilación auricular en la miocardiopatía hipertrófica obstructiva. La compañía ofrecerá además un webcast para inversores el 2 de septiembre de 2025 para comentar los resultados de MAPLE-HCM y el resto de los datos presentados.
Cytokinetics (NASDAQ:CYTK)는 스페인 마드리드에서 열리는 유럽심장학회 학술대회 2025에서 아피캠텐(aficamten)에 관한 5건의 발표를 예정했다고 발표했습니다. 주요 하이라이트로는 폐쇄성 비대심근병증(obstructive HCM) 환자에서 아피캠텐과 메토프로롤을 비교한 MAPLE-HCM 연구 결과의 Hot Line 발표가 포함됩니다.
발표에는 REDWOOD-HCM, SEQUOIA-HCM, FOREST-HCM 등 여러 임상시험의 데이터가 포함되며, 아피캠텐의 효능·안전성 및 폐쇄성 비대심근병증에서의 심방세동에 대한 영향에 중점을 둡니다. 회사는 또한 2025년 9월 2일에 MAPLE-HCM 결과와 기타 발표 데이터를 논의하는 투자자 대상 웹캐스트를 진행할 예정입니다.
Cytokinetics (NASDAQ:CYTK) a annoncé cinq communications concernant l’aficamten au Congrès de la Société Européenne de Cardiologie 2025 à Madrid, Espagne. Le point fort est une présentation Hot Line des résultats de l’étude MAPLE-HCM, comparant aficamten au métoprolol chez des patients atteints de CMH obstructive.
Les présentations porteront sur des données issues de plusieurs essais cliniques, notamment REDWOOD-HCM, SEQUOIA-HCM et FOREST-HCM, en se concentrant sur l’efficacité et la sécurité de l’aficamten ainsi que son impact sur la fibrillation atriale dans la cardiomyopathie hypertrophique obstructive. La société organisera également un webinaire pour les investisseurs le 2 septembre 2025 afin de discuter des résultats de MAPLE-HCM et des autres données présentées.
Cytokinetics (NASDAQ:CYTK) kündigte fünf Präsentationen zu Aficamten auf dem European Society of Cardiology Congress 2025 in Madrid, Spanien, an. Ein zentrales Highlight ist eine Hot-Line-Präsentation der Ergebnisse der MAPLE-HCM-Studie, in der Aficamten mit Metoprolol bei Patienten mit obstruktiver HCM verglichen wird.
Die Präsentationen zeigen Daten aus mehreren klinischen Studien, darunter REDWOOD-HCM, SEQUOIA-HCM und FOREST-HCM, und beleuchten Wirksamkeit, Sicherheit von Aficamten sowie dessen Einfluss auf Vorhofflimmern bei obstruktiver hypertropher Kardiomyopathie. Das Unternehmen wird am 2. September 2025 zudem ein Investoren-Webcast abhalten, um die MAPLE-HCM-Ergebnisse und weitere vorgestellte Daten zu erläutern.
- None.
- None.
Insights
Cytokinetics will present significant clinical data on aficamten across five presentations at ESC 2025, highlighting its potential in treating obstructive HCM.
The upcoming European Society of Cardiology Congress 2025 represents a pivotal moment for Cytokinetics' aficamten program with five separate presentations showcasing the drug's clinical performance in obstructive hypertrophic cardiomyopathy (HCM). The most significant presentation will be the primary results from MAPLE-HCM, a head-to-head comparison of aficamten versus metoprolol, which will be featured in the prestigious Hot Line session. This direct comparison against a standard-of-care beta-blocker is critically important for establishing aficamten's clinical value proposition.
A second key presentation will examine the incidence and impact of atrial fibrillation across three clinical trials of aficamten (REDWOOD-HCM, SEQUOIA-HCM and FOREST-HCM). This is particularly relevant as atrial fibrillation affects approximately 20-25% of HCM patients and significantly increases stroke risk and mortality. Understanding aficamten's effect on this common complication could differentiate it from other treatments.
Additional presentations will cover long-term safety and efficacy data from FOREST-HCM, effects on cardiac structure and function from MAPLE-HCM, and an integrated safety analysis across trials. Collectively, these presentations will provide a comprehensive assessment of aficamten's clinical profile, including efficacy, safety, and potential advantages over current standard therapy.
The prominence of these presentations at a major cardiology congress, particularly the inclusion in Hot Line and Late-Breaking sessions, suggests Cytokinetics has confidence in positive results. For patients with obstructive HCM, who currently have limited treatment options that directly address the underlying pathophysiology, aficamten represents a potential paradigm shift in management by directly targeting cardiac contractility through myosin inhibition rather than merely controlling symptoms.
Positive Results from MAPLE-HCM to be Shared in Hot Line Presentation
Late Breaking Clinical Science Session to Present Incidence and Impact of Atrial Fibrillation Across Three Clinical Trials of Aficamten in Obstructive Hypertrophic Cardiomyopathy
Company to Host Investor Event and Webcast Tuesday September 2, 2025, at 8:00 AM Eastern Time
SOUTH SAN FRANCISCO, Calif., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced five presentations related to aficamten at the European Society of Cardiology Congress 2025 taking place in Madrid, Spain from August 29, 2025 – September 1, 2025 including a Hot Line presentation of the primary results from MAPLE-HCM (Metoprolol vs Aficamten in Patients with LVOT Obstruction on Exercise Capacity in HCM) and a Late Breaking Clinical Science presentation relating to the incidence and impact of atrial fibrillation across three clinical trials of aficamten in obstructive hypertrophic cardiomyopathy (HCM).
Oral Presentations
Title: MAPLE-HCM: Aficamten vs Metoprolol in Obstructive HCM
Presenter: Pablo Garcia-Pavia, M.D., Ph.D., Head of the Inherited Cardiac Diseases and Heart Failure Unit, Department of Cardiology, Hospital Universitario Puerta de Hierro and Full Professor, Centro Nacional de Investigaciones Cardiovasculares both in Madrid, Spain
Date: August 30, 2025
Session Title: Hot Line 2
Session Time: 8:15 - 9:45 AM CEST
Presentation Time: 9:18 AM CEST
Location: Madrid (Main Auditorium)
Title: REDWOOD-HCM, SEQUOIA-HCM and FOREST-HCM Trials: Incidence and Impact of Atrial Fibrillation in Obstructive HCM with Aficamten
Presenter: Ahmad Masri, M.D., MS, Director of the Hypertrophic Cardiomyopathy Center at Oregon Health & Science University
Date: August 31, 2025
Session Title: Late-Breaking Clinical Science: Cardiomyopathies
Session Time: 4:15-5:15 PM CEST
Presentation Time: 4:45 PM CEST
Location: Budapest (Hall 10)
Title: Efficacy and Safety of Long-Term Treatment with Aficamten in Patients with Symptomatic Obstructive Hypertrophic Cardiomyopathy: Results from FOREST-HCM
Presenter: Sara Saberi, M.D., M.S., Associate Professor of Internal Medicine, University of Michigan Health Frankel Cardiovascular Center
Date: August 31, 2025
Session Title: Hypertrophic Cardiomyopathy: From Gene to Treatment
Session Time: 5:00 - 6:20 PM CEST
Presentation Time: 5:40 PM CEST
Location: Science Box 4 (Research Gateway)
Title: Effect of Aficamten Compared with Metoprolol on Cardiac Structure and Function in Symptomatic Obstructive Hypertrophic Cardiomyopathy: A Pre-Specified Analysis of MAPLE-HCM
Presenter: Sheila Hegde, M.D., M.P.H, Assistant Professor, UT Southwestern Medical Center, Dallas, TX, Affiliate Faculty, Brigham and Women's Hospital, Boston, MA
Date: August 31, 2025
Session Title: Hypertrophic Cardiomyopathy: From Gene to Treatment
Session Time: 5:00 - 6:20 PM CEST
Presentation Time: 6:10 PM CEST
Location: Science Box 4 (Research Gateway)
Moderated Poster Presentation
Title: Aficamten in Patients with Obstructive Hypertrophic Cardiomyopathy: An Integrated Safety Analysis
Presenter: Ahmad Masri, M.D., MS, Director of the Hypertrophic Cardiomyopathy Center at Oregon Health & Science University
Date: August 30, 2025
Session Title: Translating Improved Disease Understanding to Novel Therapies in Myocardial Disease
Session Time: 4:15 – 5:00 PM CEST
Location: Station 8 (Research Gateway)
Investor Webcast Information
Cytokinetics will host an investor webcast on September 2, 2025, at 8:30 AM Eastern Time to discuss the primary results from MAPLE-HCM and other data presented at the European Society of Cardiology Congress 2025. Interested parties can register online at https://cytokinetics-esc-2025.open-exchange.net/. The live webcast will be available on the Investors & Media section of the Cytokinetics website at www.cytokinetics.com. A replay of the webcast will be archived on the Cytokinetics website for six months.
About Cytokinetics
Cytokinetics is a specialty cardiovascular biopharmaceutical company, building on its over 25 years of pioneering scientific innovations in muscle biology, and advancing a pipeline of potential new medicines for patients suffering from diseases of cardiac muscle dysfunction. Cytokinetics is readying for potential regulatory approvals and commercialization of aficamten, a cardiac myosin inhibitor, following positive results from SEQUOIA-HCM, the pivotal Phase 3 clinical trial in patients with obstructive hypertrophic cardiomyopathy (HCM). Aficamten is also being evaluated in additional clinical trials enrolling patients with obstructive and non-obstructive HCM. In addition, Cytokinetics is developing omecamtiv mecarbil, a cardiac myosin activator, in patients with heart failure with severely reduced ejection fraction (HFrEF), ulacamten, a cardiac myosin inhibitor with a mechanism of action distinct from aficamten, for the potential treatment of heart failure with preserved ejection fraction (HFpEF) and CK-089, a fast skeletal muscle troponin activator with potential therapeutic application to a specific type of muscular dystrophy and other conditions of impaired skeletal muscle function.
For additional information about Cytokinetics, visit www.cytokinetics.com and follow us on X, LinkedIn, Facebook and YouTube.
Forward-Looking Statements
This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). Cytokinetics disclaims any intent or obligation to update these forward-looking statements and claims the protection of the Act's Safe Harbor for forward-looking statements. Examples of such statements include, but are not limited to, statements relating to any of our clinical trials, statements relating to the potential benefits of aficamten or any of our other drug candidates. Cytokinetics' research and development activities; the design, timing, results, significance and utility of preclinical and clinical results; and the properties and potential benefits of Cytokinetics' other drug candidates. Such statements are based on management's current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to, potential difficulties or delays in the development, testing, regulatory approvals for trial commencement, progression or product sale or manufacturing, or production of Cytokinetics' drug candidates that could slow or prevent clinical development or product approval; Cytokinetics' drug candidates may have adverse side effects or inadequate therapeutic efficacy; the FDA or foreign regulatory agencies may delay or limit Cytokinetics' ability to conduct clinical trials; Cytokinetics may be unable to obtain or maintain patent or trade secret protection for its intellectual property; standards of care may change, rendering Cytokinetics' drug candidates obsolete; and competitive products or alternative therapies may be developed by others for the treatment of indications Cytokinetics' drug candidates and potential drug candidates may target. For further information regarding these and other risks related to Cytokinetics' business, investors should consult Cytokinetics' filings with the Securities and Exchange Commission.
CYTOKINETICS® and the CYTOKINETICS and C-shaped logo are registered trademarks of Cytokinetics in the U.S. and certain other countries.
Contact:
Cytokinetics
Diane Weiser
Senior Vice President, Corporate Affairs
(415) 290-7757
FAQ
When is Cytokinetics (CYTK) presenting MAPLE-HCM results at ESC Congress 2025?
What clinical trials of aficamten will be discussed at the ESC Congress 2025?
When is the Cytokinetics investor webcast for ESC Congress 2025 data?
How many presentations will Cytokinetics deliver about aficamten at ESC 2025?
